AP 161
Alternative Names: AP-161Latest Information Update: 23 Apr 2024
At a glance
- Originator Alphageneron Pharmaceuticals
- Class Antineoplastics; Immunotherapies; Natural killer cell therapies
- Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Colorectal cancer; Non-small cell lung cancer; Pancreatic cancer
Most Recent Events
- 10 Apr 2024 Preclinical trials in Colorectal cancer in Germany (IV) (Alphageneron Pharmaceuticals Pipeline, Prior to April 2024)
- 10 Apr 2024 Preclinical trials in Non-small cell lung cancer in Germany (IV) (Alphageneron Pharmaceuticals Pipeline, Prior to April 2024)
- 10 Apr 2024 Preclinical trials in Pancreatic cancer in Germany (IV) (Alphageneron Pharmaceuticals Pipeline, Prior to April 2024)